Anti-Inflammatory Effects of Taraxasterol on LPS-Stimulated Human Umbilical Vein Endothelial Cells

[1]  Wang Tiejun,et al.  Taraxasterol inhibits cigarette smoke-induced lung inflammation by inhibiting reactive oxygen species-induced TLR4 trafficking to lipid rafts. , 2016, European journal of pharmacology.

[2]  Xuemei Zhang,et al.  Anti-inflammatory and anti-arthritic effects of taraxasterol on adjuvant-induced arthritis in rats. , 2016, Journal of ethnopharmacology.

[3]  Changming Guo,et al.  Morin suppresses inflammatory cytokine expression by downregulation of nuclear factor-κB and mitogen-activated protein kinase (MAPK) signaling pathways in lipopolysaccharide-stimulated primary bovine mammary epithelial cells. , 2016, Journal of dairy science.

[4]  Xuemei Zhang,et al.  Effects of taraxasterol on iNOS and COX-2 expression in LPS-induced RAW 264.7 macrophages. , 2014, Journal of ethnopharmacology.

[5]  Yunhe Fu,et al.  Cyanidin-3-O-β-glucoside inhibits lipopolysaccharide-induced inflammatory response in mouse mastitis model , 2014, Journal of Lipid Research.

[6]  Yunhe Fu,et al.  Protective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in mice. , 2014, International immunopharmacology.

[7]  Xuemei Zhang,et al.  Protective effect of taraxasterol against LPS-induced endotoxic shock by modulating inflammatory responses in mice , 2014, Immunopharmacology and immunotoxicology.

[8]  Xuemei Zhang,et al.  Effects of taraxasterol on ovalbumin-induced allergic asthma in mice. , 2013, Journal of Ethnopharmacology.

[9]  Qinglin Yang,et al.  Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. , 2009, Cardiovascular research.

[10]  R. Khalil,et al.  Inflammatory cytokines in vascular dysfunction and vascular disease. , 2009, Biochemical pharmacology.

[11]  W. McNicholas,et al.  Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? , 2009, Thorax.

[12]  B. Larijani,et al.  A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. , 2009, Inflammation & allergy drug targets.

[13]  A. Lusis,et al.  Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE , 2007 .

[14]  D. Bruemmer,et al.  Liver x receptors: potential novel targets in cardiovascular diseases. , 2005, Current drug targets. Cardiovascular & haematological disorders.

[15]  P. Scherer,et al.  Adipose tissue, inflammation, and cardiovascular disease. , 2005, Circulation research.

[16]  D. Mangelsdorf,et al.  Liver X receptor signaling pathways in cardiovascular disease. , 2003, Molecular endocrinology.

[17]  E. Nardin.  The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. , 2001 .

[18]  R. Hofer-Warbinek,et al.  The Transcription Factor NF-κB and the Regulation of Vascular Cell Function , 2000 .

[19]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[20]  É. Allaire,et al.  Endothelial cell injury in cardiovascular surgery: atherosclerosis. , 1997, The Annals of thoracic surgery.

[21]  A. Lusis,et al.  Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. , 2007, The Journal of clinical investigation.

[22]  P. Black,et al.  Stress, inflammation and cardiovascular disease. , 2002, Journal of psychosomatic research.

[23]  R. Hofer-Warbinek,et al.  The transcription factor NF-kappa B and the regulation of vascular cell function. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  E D Verrier,et al.  Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. , 1997, The Annals of thoracic surgery.